Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Shaw

Showing results (601-610 of 617) with videos related to

Pageof 62
Sort By:
Nature Communications|October 28, 2014
Extant diversity of bryophytes emerged from successive post-Mesozoic diversification burstsB Laenen, B Shaw, H Schneider, et al.
Neuropharmacology|September 28, 2013
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disordersLinda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, et al.
Proteomics|March 20, 2014
The first pilot project of the consortium for top-down proteomics: a status reportXibei Dang, Jenna Scotcher, Si Wu, et al.
Journal of Medicinal Chemistry|January 20, 2018
Synthesis and Pharmacological Characterization of C4<sub>β</sub>-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu<sub>3</sub> Receptor AgonistJames A Monn, Steven S Henry, Steven M Massey, et al.
Spinal Cord|October 6, 2018
Correction: Evidence-based scientific exercise guidelines for adults with spinal cord injury: an update and a new guidelineKathleen A Martin Ginis, Jan W van der Scheer, Amy E Latimer-Cheung, et al.
Journal of Medicinal Chemistry|August 28, 2015
Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor AgonistJames A Monn, Lourdes Prieto, Lorena Taboada, et al.
Spinal Cord|October 27, 2017
Evidence-based scientific exercise guidelines for adults with spinal cord injury: an update and a new guidelineKathleen A Martin Ginis, Jan W van der Scheer, Amy E Latimer-Cheung, et al.
Spinal Cord|January 20, 2018
Response to correspondence from the ESSA Statement authorsKathleen A Martin Ginis, Jan W van der Scheer, Amy E Latimer-Cheung, et al.
Neurosurgical Focus|March 31, 2021
Biographies of international women leaders in neurosurgeryStephanie M Casillo, Anisha Venkatesh, Nallammai Muthiah, et al.
Journal of Medicinal Chemistry|January 21, 2015
Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structuresJames A Monn, Lourdes Prieto, Lorena Taboada, et al.
Pageof 62

Showing results (601-610 of 617) with videos related to

Sort By:
Pageof 62
Nature Communications|October 28, 2014
Extant diversity of bryophytes emerged from successive post-Mesozoic diversification burstsB Laenen, B Shaw, H Schneider, et al.
Neuropharmacology|September 28, 2013
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disordersLinda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, et al.
Proteomics|March 20, 2014
The first pilot project of the consortium for top-down proteomics: a status reportXibei Dang, Jenna Scotcher, Si Wu, et al.
Journal of Medicinal Chemistry|January 20, 2018
Synthesis and Pharmacological Characterization of C4<sub>β</sub>-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu<sub>3</sub> Receptor AgonistJames A Monn, Steven S Henry, Steven M Massey, et al.
Spinal Cord|October 6, 2018
Correction: Evidence-based scientific exercise guidelines for adults with spinal cord injury: an update and a new guidelineKathleen A Martin Ginis, Jan W van der Scheer, Amy E Latimer-Cheung, et al.
Journal of Medicinal Chemistry|August 28, 2015
Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor AgonistJames A Monn, Lourdes Prieto, Lorena Taboada, et al.
Spinal Cord|October 27, 2017
Evidence-based scientific exercise guidelines for adults with spinal cord injury: an update and a new guidelineKathleen A Martin Ginis, Jan W van der Scheer, Amy E Latimer-Cheung, et al.
Spinal Cord|January 20, 2018
Response to correspondence from the ESSA Statement authorsKathleen A Martin Ginis, Jan W van der Scheer, Amy E Latimer-Cheung, et al.
Neurosurgical Focus|March 31, 2021
Biographies of international women leaders in neurosurgeryStephanie M Casillo, Anisha Venkatesh, Nallammai Muthiah, et al.
Journal of Medicinal Chemistry|January 21, 2015
Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structuresJames A Monn, Lourdes Prieto, Lorena Taboada, et al.
Pageof 62